Stealth Adapted Viruses

Stealth Adapted Viruses

Dr. John Martin is the original whistleblower on ‘stealth viral contamination’ of vaccinations. His tenure spanned 70’s, 80’s, and 90’s during which time he held many prominent positions including the FDA, Virology Department and the National Cancer Institute, Biological Resources Branch.

In his own words:

“What makes vaccines so troublesome is that their production and administration allows viral contamination to breach the two natural barriers that often restrict cross-species infections:

First is the skin. Direct inoculation of vaccines breaches this natural barrier and has been shown to produce increased infections in animals and humans. Such was the case when SV40 was injected intramuscularly in contaminated Salk polio vaccine. Later it was learned that Sabin’s orally administered polio vaccines were safer since the live simian viruses were digested in the stomach and thereby inactivated. Additionally risky, when it comes to breaking the skin barrier, is the chance of transmitting viruses from one person to another through the use of unsterilized needles.

Second is the unique and natural viral surface characteristics that reduce the chance that viruses might jump species. The mixing of vaccine viruses with others found in the cells and tissues used to develop the vaccine can potentially lead to the development of new recombinant mutants that are more adaptive and have wider host range than either of the original viruses. This can especially happen when a live viral vaccine produced in cells from one species is then given to another species.

Also of concern is the transmission of new genetic information along with the vaccine virus. For instance, early adenoviral vaccines, produced in rhesus monkeys’ kidney cells, developed to protect people against respiratory infections, incorporated parts ofthe SV40 virus that remained as a vaccine contaminant even after production of the vaccine virus was switched to human cells. Numerous other vaccines, especially those that were used in early field trials in Africa, should be analyzed for those genetic components which characterize today’s monkey and human pathogens.

Unfortunately, this new awareness of potential problems with live viral vaccines has had little impact on the viral vaccine approval process. Seemingly, U.S. government agencies, principally the FDA, have been reluctant to impose additional testing requirements on vaccines once they are approved for use. In effect, government officials are given a single opportunity to decide on a new vaccine’s safety. Even then, government regulators themselves may be denied certain critical information belonging to the vaccine industry. Specifically, FDA regulations are written so as not to compel industry to reveal testing information not directly pertaining to the lots submitted for clinical use. The FDA is reluctant to admit its lack of knowledge about vaccines to the medical/scientific community. Yet, practicing physicians are expected to unquestionably endorse the safety of vaccines under all circumstances and to all individuals.”

He rang the alarm bell all those years ago and the FDA is only just now beginning the discussion of “stealth viruses in cell lines”….

FDA says:

“Some of these tumor-forming cell lines may contain cancer-causing viruses that are not actively reproducing. Such viruses are hard to detect using standard methods. These latent, or “quiet,” viruses pose a potential threat, since they might become active under vaccine manufacturing conditions. Therefore, to ensure the safety of vaccines, our laboratory is investigating ways to activate latent viruses in cell lines and to detect the activated viruses, as well as other unknown viruses, using new technologies.”

You can read more here:

To learn more about the impact of vaccination on the human genome — and on your genes, attend our upcoming (MARCH 3, 2018) Future of Immunity Lecture: Genes and Vaccines at the University of Washington, Bothell. Details can be found HERE.

Comments are closed.